A primary challenge in the diagnosis of neurological disorders is differentiating between conditions that share clinical features. Absent of a clear diagnosis, proper
and effective patient care is hindered. Therefore, there is a great need for accessible diagnostic tools that help provide clarity to diagnosing clinicians.
Researchers from La Jolla Institute for Immunology have discovered a genetic signature on the circulating T cells of patients with Parkinson’s disease, which they hope can provide new avenues of research for potential treatments.
Vaxxinity, a “purpose-driven biotechnology company committed to democratizing healthcare across the globe,” announced that it has dosed its first patient with Parkinson’s disease in a Phase 1 study of the vaccine UB-312.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded two grants to AC Immune, a Swiss-based biopharmaceutical company, to support the development of molecules designed to stop the accumulation of alpha-synuclein and inhibit an inflammatory pathway in Parkinson’s disease.
Boston- and Atlanta-based clinical-stage pharmaceutical company Inhibikase Therapeutics, Inc. published the biochemical rationale for potentially treating Parkinson’s disease with IkT-148009, a highly selective Abelson Tyrosine Kinase (c-Abl) inhibitor.
Boston-based biopharma company Yumanity Therapeutics announced last week that its drug candidate, YTX-7739, met its primary end points in a Phase 1b trial in patients with mild to moderate Parkinson’s disease.
A monoclonal antibody that binds to alpha-synuclein is advancing into a clinical trial after showing positive results in the preclinical phase. The compound, known as ABBV-0805, was developed in collaboration between AbbVie and BioArctic, a Swedish biopharma company that focuses on neurodegenerative diseases.
A hallmark of Parkinson’s disease is the presence of Lewy bodies—abnormal clumps of protein primarily made of alpha-synuclein—the reduction of which is hypothesized to stop or slow the development and progression of Parkinson’s and related diseases such as dementia with Lewy bodies and multiple system atrophy.
Researchers at the University of Utah tested more than 150,000 compounds in search of candidates that could reduce levels of alpha-synuclein, a protein that forms clumps and kills neurons, leading to neurodegenerative diseases like Parkinson’s disease and dementia with Lewy bodies.
In a new paper published in Movement Disorders, researchers for the first time established a link between the presence of misfolded alpha-synuclein and X-linked dystonia-Parkinsonism, also known as “Lubag.”